Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389703 | 1.00 | CYP2C9 (0.32) | CYP2C9RORCKMT2A | |
| SCHEMBL2389462 | 0.95 | CYP2C9 (0.33) | CYP2C9RORC | |
| SCHEMBL2389465 | 0.95 | CYP2C9 (0.33) | CYP2C9RORC | |
| SCHEMBL2390898 | 0.94 | RORC (0.33) | CYP2C9RORCKMT2A | |
| SCHEMBL2390896 | 0.94 | RORC (0.33) | CYP2C9RORCKMT2A | |
| SCHEMBL2387359 | 0.94 | CYP2C9 (0.31) | CYP2C9RORC | |
| SCHEMBL2387362 | 0.94 | CYP2C9 (0.31) | CYP2C9RORC | |
| SCHEMBL1517913 | 0.93 | CYP2C9 (0.33) | CYP2C9RORCKMT2A | |
| SCHEMBL1517914 | 0.93 | CYP2C9 (0.33) | CYP2C9RORCKMT2A | |
| SCHEMBL2389128 | 0.93 | REN (0.32) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022069-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2011-09-20 | — | — | US | disclosed |
| US-20100331322-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2250166-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009098276-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331322-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | REN, ACE, AGTR1 | CYP2C9 239/4885RORC 2407/4885KMT2A 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.